The structures of these novel drug leads are different from the first Nutlin lead RG7112 and include: (i) AMG232 for use in glioblastoma [10]; (ii) the stapled peptide ALRN-6924 that binds to the p53-binding pocket for use in solid tumors or lymphomas [11]; and (iii) RG7388 that is being tested alone and in combination with other chemical agents for use in essential thrombocythemia and polycythemia vera. The gene discussed is TP53; the disease is essential thrombocythemia.